Evolving therapeutic paradigms for HIV and HCV

Current Opinion in Biotechnology

Volumn 14, Issue 6, 2003, Pages 634-640

  Molla, Akhteruzzaman ^a   Kohlbrenner, William ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 3 O (3,3 DIMETHYLSUCCINYL)BETULIC ACID; ABACAVIR; AMPRENAVIR; ANTIVIRUS AGENT; ATAZANAVIR; CAPRAVIRINE; CD4 IMMUNOGLOBULIN G2; DARUNAVIR; DELAVIRDINE; DIDANOSINE; DPC 083 023; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; GAMMA INTERFERON; GW 8248; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; MARAVIROC; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NAPHTHYRIDINE DERIVATIVE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; RO 033 4649; SAQUINAVIR; SM 309515; SPD 754; STAVUDINE; T 1249; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

AGITATION; ANEMIA; BIOAVAILABILITY; BIOTECHNOLOGY; DIARRHEA; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; NONHUMAN; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; SLEEP DISORDER;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0345118203     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2003.10.012     Document Type: Review

References (37)

1. Borroto-Esoda K, Waters J, Quinn, JB, Shaw A, Hinkle J, Rousseau F, FTC-301 study team: Characterization of baseline and treatment-emergent resistance mutations following one year of therapy on an entirely once a day regimen including emtricitabine. In Proceedings of the XII International HIV Drug Resistant Workshop: 2003 June 10-14; Los Cabos, Mexico: Abstract 7.
2. Margot N.A., Isaacson E., McGowan I., Cheng A.K., Schooley R.T., Miller M.D. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofavir DF. AIDS. 16:2002;1227-1235.
3. Gilden D: Nucleoside analog toxicity insidiously impairs cell energy production. American Foundation for AIDS Res 2000:1-11.
4. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev. 16:1996;125-157.
5. Eron J, Da Silva B, King M, Gulick R, Benson C, White AC, Glesby M, Thompson M, Albrecht M, Wolfe P et al.: Lopinavir/ritonavir in antiretroviral-naïve HIV-infected patients: five-year follow up. In Proceedings of the 43rd Interscience Conference on Antiretroviral agents and Chemotherapy: 2003 Sep 14-17; Chicago: Abstract H-844.
6. th Conference on Retrovirus and Opportunistic Infections: 2001 Feb 4-8; Chicago: Abstract 525.
7. Reyataz: (Atazanavir) package insert. URL: http://www.BMS.com Compares an atazanavir-containing regimen with LPV/r: the atazanavir-containing regimen was inferior to the LPV/r-containing regimen.
8. Sanne I, Cahn P, Percival L, Phanuphaak P, Kelleher T, Wellens I, Giordano M: Pantaleo, and the BMS-008 International trial group: Comparative results: BMS-232632, stavudin, lamivudin as HAART in treatment-naïve patients. In Proceedings of the 4Ist Interscience Conference on Antiretroviral agents and Chemotherapy: 2001, Dec 16-19; Chicago: Abstract I-667.
9. Yeni P.G., Hammer S.M., Carpenter C.C., Cooper D.A., Fischl M.A., Gatell J.M., Gazzard B.G., Hirsch M.S., Jacobsen D.M., Katzenstein D.A.et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the international AIDS society-USA panel. JAMA. 288:2002;222-235.
10. Kirk O., Katzenstein T.L., Gerstoft J., Mathiesen L., Nielsen H., Pedersen C., Lundgren J.D. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trials. AIDS. 13:1999;F9-16.
11. Lalezari J.P., Eron J.J., Carlson M., Cohen C., Dejesus E., Arduino R.C., Gallant J.E., Volberding P., Murphy R.L., Valentine F.et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS. 17:2003;691-698.
12. th Conference on Retroviruses and Opportunistic Infections: 2002 Feb 24-28; Seattle: Abstract 8.
13. Hazuda DJ, and the MRL HIV-1 drug discovery team: The identification of active site mutations that confer resistance to structurally diverse inhibitors of HIV-1 integrase strand transfer supports a general mechanism of phosphotransferase inhibiton. In Proceedings of the XII International Drug Resistance Workshop: Basic principles and clinical implications, Antiviral Therapy: 2003 Jun 10-14; Cabo San Lucas, Mexico: Abstract 10.
14. rd Annual Meeting: 2002 Nov 1-5; Boston: Abstract 464.
15. rd Annual Meeting: 2002 Nov 1-5; Boston: Abstract 563.
16. Idnex Pharmaceuticals Inc: NM283 shows promise. 2003; Press release. URL: http://www.idinix.com.
17. Carroll S.S., Tomassini J.E., Bosserman M., Getty K., Stahlhutt M.W., Eldrup A.B., Bhat B., Hall D., Simcoe A.L., LaFemina R.et al. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278:2003;11979-11984.
18. th Conference on Retroviruses and Opportunistic Infections: 2003 Feb 10-14; Boston: Abstract 8.
19. th Conference on Retroviruses and Opportunistic Infections: 2003 Feb 10-14; Boston: Abstract 179.
20. Mimoto T, Nojima S, Terashima K, Takaku H, Chiba N, Shintani M, Yamaoka T, Hayashi H: SM-309515: a novel and promising HIV protease inhibitor with favorable pharmacokinetics and resistance profiles. In Proceedings of the 43rd Interscience Conference on Antiretroviral agents and Chemotherapy: 2003 Sep 14-17; Chicago: Abstract H-873.
21. th Conference on Retroviruses and Opportunistic Infections: 2003 Feb 10-14; Boston: Abstract 7.
22. Cahn P, Van Leeuwen R, Sawyer J, Shiveley L: Tolerability and ant-HIV activity of SPD754 in 10 days monotherapy in treatment naïve patients. In Proceedings of the 43rd Interscience Conference on Antiretroviral agents and Chemotherapy: 2003 Sep 14-17; Chicago: Abstract H-869.
23. Burnette TC, Marr H, Owens B, Wheelan P, Moore K: Interspecies pharmacokinetics and scalling of GW8248, a novel non-nucleoside HIV reverse transcriptase inhibitor and its prodrug GW5634. In Proceedings of the 43rd Interscience Conference on Antiretroviral agents and Chemotherapy: 2003 Sep 14-17; Chicago: Abstract F-1837.
24. Hazen RJ, Harvey R, Ferris R, Creech K, Clair M, Romines K, Freeman G, Schaller L, Chan J, Dornsife R, et al.: Characterization of the anti-HIV activity of GW8248 in combination with other antiretroviral drugs and in vitro selection of resistance. In Proceedings of the 43rd Interscience Conference on Antiretroviral agents and Chemotherapy: 2003 Sep 14-17; Chicago: Abstract H-445.
25. Hammond JL, Amantea M, Raber S, Grettenberger H, Shetty B, Pesano R, Patick AK, Hawley P: Long-term virologic response to capravirin in HIV infected NNRTI-experienced patients. In Proceedings of the 43rd Interscience Conference on Antiretroviral agents and Chemotherapy: 2003 Sep 14-17; Chicago: Abstract H-871.
26. th Conference on Retroviruses and Opportunistic Infections: 2002 Feb 24-28; Seattle: Abstract 4.
27. th Conference on Retroviruses and Opportunistic Infections: 2002 Feb 24-28; Seattle: Abstract 6.
28. Lalezari JP, Bellos N, Richmond G, Sathasivam K, Cohen C, Myers R, Henry D, Raskino C, Zhang Y, Spence B et al.: Final analysis of T1249-102: T-1249 retains potent short-term antiviral activity in patients who have failed a regimen containing enfuvirtide (ENF). In Proceedings of the 43rd Interscience Conference on Antiretroviral agents and Chemotherapy: 2003 Sep 14-17; Chicago: Abstract H-444.
29. th Conference on Retroviruses and Opportunistic Infections: 2003 Feb 10-14; Boston: Abstract 561.
30. Russell D, Bakhtyari A, Jazrawi RP, Whitlock L, Ridgway C, Mchale M, Abel S: Multiple dose study to investigate the safety of UK-427,857 (100 mg or 300 mg) BID for 28 days in healthy males and females. In Proceedings of the 43rd Interscience Conference on Antiretroviral agents and Chemotherapy: 2003 Sep 14-17; Chicago: Abstract H-874.
31. Pozniak AL, Fatkenheuer G, Johnson M, Hoepelman IM, Rockstroh J, Goebel F, Abel S, James I, Rosario M, Medhurst C et al.: Effect of short-term monotherapy with UK-427,857 on viral load in HIV infected patients. In Proceedings of the 43rd Interscience Conference on Antiretroviral agents and Chemotherapy: 2003 Sep 14-17; Chicago: Abstract H-443.
32. th Conference on Retroviruses and Opportunistic Infections: 2002 Feb 24-28; Seattle: Abstract 1.
33. th Conference on Retroviruses and Opportunistic Infections: 2003 Feb 24-28; Boston: Abstract 14.
34. Mo H., Lu L., Dekhtyar T., Stewart K.D., Sun E., Kempf D.J., Molla A. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir. Antiviral Res. 59:2003;173-180 Describes the in vitro resistance profile of LPV selected during passage with LPV alone or in combination with LPV and ritonavir.
35. Kempf D.J., Isaacson J.D., King M., Brun S.C., Xu Y., Real K., Bernstein B.M., Japour A.J., Sun E., Rode R.A. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:2001;7462-7469 Describes the relationship between protease mutations and susceptibility to the HIV protease inhibitor lopinavir.
36. Parkin N.T., Chappey C., Petropoulos C.J. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS. 17:2003;955-961.
37. Colonno R.J., Thiry A., Limoli K., Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob. Agents Chemother. 47:2003;1324-1333 Describes the cross-resistance profile of the new protease inhibitor atazanavir to a large panel of clinical isolates exhibiting a wide array of protease inhibitor resistance profiles.